Skip to content
Catalyst

milk thistle extract (silymarin)Finding

Milk thistle extract (silymarin) has no detected effect on serious adverse event incidence

no difference foundModerate evidenceFindingreplicated ×1

01 · The sentence it was drawn from

“Comparing placebo vs silymarin (either dose), the proportion of patients with at least 1 serious adverse event in the silymarin groups (7/102) did not differ significantly from the proportion in the placebo group (1/52) (P =.27).”
Quoted verbatim from Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
This finding among the 11 findings on its endpoint

milk thistle extract (silymarin)

Serious adverse event incidence

no difference found

Who
Adults with chronic hepatitis C who had not responded to interferon-based therapy; silymarin at either dose (420 mg or 700 mg three times daily, pooled) versus placebo
Dose studied
420 mg or 700 mg silymarin three times daily for 24 weeks

Moderate evidencePMID 22797645 · 2012

02 · The study

Study
RCT
Duration
6 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

JAMA
What else it reported2 findings · 0 compounds · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6Y29282J46EKGD5AGP47VRV